130 results on '"De, Arka"'
Search Results
2. Exploring the Prevalence, Predictors, and Impact of Bacterial Infections to Guide Empiric Antimicrobial Decisions in Cirrhosis (EPIC-AD)
3. Intravenous BCAA Infusion Does Not Lead to a Sustained Recovery From Overt HE in ACLF – An Open Label Randomized Clinical Trial
4. Burden, risk factors, and outcomes of multidrug-resistant bacterial colonisation at multiple sites in patients with cirrhosis
5. INASL–SAASL Consensus Statements on NAFLD Name Change to MAFLD
6. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
7. Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital
8. Lysosomal Acid Lipase Activity in Non-alcoholic Fatty Liver Disease as a Novel Diagnostic and Therapeutic Target: A Systematic Literature Review of Current Evidence and Future Directions
9. Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena
10. High Prevalence of Hormonal Changes and Hepatic Osteodystrophy in Frail Patients with Cirrhosis—An Observational Study
11. Tuberculosis in Cirrhosis – A Diagnostic and Management Conundrum
12. A Comparison of Different Frailty Scores and Impact of Frailty on Outcome in Patients With Cirrhosis
13. FRI-231 Compared to complete abstainers, non-significant alcohol use may be associated with more severe liver disease in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)-The multicentre study of the indian consortium on MASLD
14. FRI-082 Unveiling the role of GH-IGF1 axis in decompensated cirrhosis: implications for sarcopenia, frailty, decompensations, and mortality
15. THU-051 Extended validation of proteomics and machine learning guided biomarker discovery and pathway perturbations in infectionrelated acute-on-chronic liver failure
16. SAT-295 Sarcopenia, frailty and growth hormone-insulin like growth factor axis among decompensated and alcohol-associated hepatitis patients
17. THU-324 Differential apoptotic and non-apoptotic cell death profiles in alcohol associated liver disease and their prognostic impact on acute-on-chronic liver failure
18. Bloody Lips - Gluing Bleeding Lower Lip Spider Angioma in Decompensated Cirrhosis
19. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD
20. Fingolimod, a sphingosine-1-phosphate agonist for the treatment of hepatopulmonary syndrome: Queries and concerns
21. OS-064-YI - Calorie restriction by time restricted intermittent fasting is better than standard calorie restriction in improving the metabolic profile and hepatic fibrosis in patients with non-alcoholic fatty liver disease
22. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis – Validation in an Indian Cohort.
23. Exploring the Prevalence, Predictors and Impact of Bacterial Infections and Guiding Empiric Antimicrobial Decisions in Acutely Decompensated Cirrhosis (EPIC-AD): A-seminal
24. A comprehensive Analysis of the Impact of the Growth Hormone-insulin Like Growth Factor Levels on Complications, Autonomic Neuropathy, and Prognosis in Cirrhosis
25. Impact of outpatient intensive nutrition therapy on survival and frailty in patients with Acute on Chronic Liver Failure - Randomised controlled trial
26. An Observational Study to Determine the Combination of Precipitating Factors Predicting 30-Day Mortality in Acute-On-Chronic Liver Failure (ACLF), With Respect to Underlying Disease Etiology and definition of ACLF
27. Bedside Galactomannan Lateral Flow Assay (GM-LFA) for timely diagnosis of Invasive Pulmonary Aspergillosis In ACLF Patients
28. Endoscopic Ultrasound guided occlusion for large gastric varices Can we do away with coils?
29. Imaging and Endovascular Interventions for Portosystemic shunts in cirrhosis - An Overview
30. Combination of Locoregional Therapy (LRT) And Tyrosine Kinase Inhibitors (TKIS) is superior to LRT alone in improving the overall survival in Hepatocellular Carcinoma
31. Prevalence of Frailty in Patients with Hepatocellular Carcinoma: A real-world observational Study
32. Focal Liver Lesions a frequent Diagnostic Dilemma
33. Acute Viral Hepatitis with Prolonged Cholestasis: Role of steroids and Experimental Therapies in Management
34. Effectiveness of Time-restricted Intermittent Fasting in Patients with Non-alcoholic Fatty Liver Disease - A Randomized Controlled Trial
35. Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
36. Safety and Efficacy of Saroglitazar in Patients with Non-obese NAFLD: Open-label Randomized Control Trial
37. Validation of AGILE-3+ Score for Assessing Advanced Fibrosis in Indian Patients with Nonalcoholic Fatty Liver Disease (NAFLD): An Interim Analysis of the Multicentric Indian Consortium on NAFLD (ICON D) Study
38. Validation of AGILE-4 Score for Assessing Cirrhosis in Indian Patients with Nonalcoholic Fatty Liver Disease (NAFLD): An Interim Analysis of the Multicentric Indian Consortium on Nafld (ICON D) Study
39. Predictors of Coronary Artery Disease (CAD) In Potential Liver Transplant (LT) Recipients and Performance ofThe CAD-LT Score In Identifying A Risk-Based Strategy For CAD
40. EUS guided liver biopsy in patients with suspected cACLD and cirrhosis: a real-life observational study
41. An enigmatic case of hypereosinophilia
42. Urinary Proteomics Unveil Prognostic Biomarkers in Acute Kidney Injury with Decompensated Cirrhosis
43. Integrated Unsupervised and Supervised Machine Learning Unveils and Predicts the Clusters with Distinct Profiles and Survival in Acute-on-Chronic Liver Failure (CLUSTER-ACLF)
44. Invasive Pulmonary Aspergillosis and Tuberculosis Complicated by Hemophagocytic Lymphohistiocytosis - Sequelae of COVID-19 in a Liver Transplant Recipient
45. IgG4-Related Sclerosing Cholangitis with Cholecystitis Mimicking Cholangiocarcinoma: A Case Report
46. Long-term efficacy and safety of oral nucleoside/tide analogues in maintaining biochemical and virological remission in renal transplant recipients with hepatitis B virus (HBV) infection.
47. Dual energy X-ray absorptiometry (DEXA) for fracture risk assessment in Hepatitis C virus (HCV)-related compensated advanced chronic liver disease (cACLD) using FRAX tool
48. Efficacy and safety of pan-genotypic Sofosbuvir and Velpatasvir in patients with Hepatitis C reinfection following attainment of sustained virological response with NS5A inhibitors
49. Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with chronic hepatitis c and HIV co-infection on dolutegravir-based anti-retroviral therapy
50. Patients with metabolic-dysfunction associated fatty liver disease (MAFLD) without associated etiologies and non-MAFLD non-alcoholic fatty liver disease (NAFLD) have similar liver disease severity - Data from Indian Consortium on NAFLD (ICON-D).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.